{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:35:59Z","timestamp":1791646559908,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merrimack Pharmaceuticals, Inc."},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejca.2018.12.007","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T09:27:09Z","timestamp":1547458029000},"page":"78-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":330,"special_numbering":"C","title":["NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors"],"prefix":"10.1016","volume":"108","author":[{"given":"Andrea","family":"Wang-Gillam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beloo","family":"Mirakhur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.12.007_bib1","series-title":"Cancer facts & figures 2017","author":"American Cancer Society","year":"2017"},{"key":"10.1016\/j.ejca.2018.12.007_bib2","series-title":"GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.ejca.2018.12.007_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","article-title":"A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs","volume":"46","author":"Carrato","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.ejca.2018.12.007_bib4","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.007_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00432-017-2349-y","article-title":"Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer","volume":"143","author":"Okusaka","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib6","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7010007","article-title":"FOLFIRINOX chemotherapy in metastatic pancreatic cancer: a systematic review and meta-analysis of retrospective and phase II studies","volume":"7","author":"Thibodeau","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2018.12.007_bib8","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3748\/wjg.v20.i9.2224","article-title":"Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?","volume":"20","author":"Walker","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2018.12.007_bib9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/IJN.S88084","article-title":"Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan","volume":"11","author":"Ko","year":"2016","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.ejca.2018.12.007_bib10","series-title":"Annual meeting of the American Association for Cancer Research. San Diego, CA","article-title":"Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI) [poster CT224]","author":"Ramanathan","year":"2014"},{"key":"10.1016\/j.ejca.2018.12.007_bib11","series-title":"Onivyde [package insert]","year":"2017"},{"key":"10.1016\/j.ejca.2018.12.007_bib12","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.12.007_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.12.007_bib14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cam4.635","article-title":"PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin\/5-fluorouracil as second-line therapy in metastatic colorectal cancer","volume":"5","author":"Chibaudel","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2018.12.007_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.critrevonc.2015.07.007","article-title":"Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials","volume":"96","author":"Nagrial","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2018.12.007_bib16","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib17","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of 5-fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"4","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ctrv.2016.09.001","article-title":"Post-gemcitabine therapy for patients with advanced pancreatic cancer - a comparative review of randomized trials evaluating oxaliplatin- and\/or irinotecan-containing regimens","volume":"50","author":"Vogel","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2018.12.007_bib19","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib20","series-title":"Pancreatic adenocarcinoma version 1.2019","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2018"},{"key":"10.1016\/j.ejca.2018.12.007_bib21","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic pancreatic cancer: ASCO clinical practice guideline update","volume":"36","author":"Sohal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2015.11.001","article-title":"Prognostic and predictive markers in pancreatic adenocarcinoma","volume":"48","author":"Le","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejca.2018.12.007_bib23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.007_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjc.6604568","article-title":"Modelling prognostic factors in advanced pancreatic cancer","volume":"99","author":"Stocken","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.12.007_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2018.12.007_bib26","series-title":"Annual congress of the European Hematology Association. Stockholm Sweden","article-title":"Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication-mutated (MUT) relapsed\/refractory AML in the phase 3, randomized, controlled Quantum-R trial [abstract LB2600]","author":"Cortes","year":"2018"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:39:19Z","timestamp":1565217559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":26,"alternative-id":["S0959804918315533"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}